Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

Phase 2 Unknown 33 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.

Timeline

Start: 2021-01-15
Primary completion: 2022-12
Completion: 2023-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	—	—

Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

Summary

Timeline

Drugs

Indications